Cellular Dissociation Grading Based on the Parameters Tumor Budding and Cell Nest Size in Pretherapeutic Biopsy Specimens Allows for Prognostic Patient Stratification in Esophageal Squamous Cell Carcinoma Independent From Clinical Staging.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 27 2 2019
medline: 20 2 2020
entrez: 27 2 2019
Statut: ppublish

Résumé

Initial treatment planning in esophageal squamous cell carcinoma mainly relies on clinical staging. Recently, a highly prognostic grading system based on the cellular dissociation parameters Tumor Budding and Cell Nest Size has been proposed for resected esophageal squamous cell carcinoma. To probe for the transferability and relevance of this established novel grading system in the pretreatment setting, we evaluated Tumor Budding/Cell Nest Size in pretherapeutic biopsies of either primarily resected (cohort 1, n=80) or neoadjuvantly treated (cohort 2, n=75) esophageal squamous cell carcinoma. Grading data were correlated with clinicopathologic and survival parameters. High Tumor Budding Activity and small Cell Nest Size in pretherapeutic biopsies were strongly associated with shortened overall survival, disease-free survival, and disease-specific survival in both cohorts. A modified histopathologic grading system incorporating both factors termed "Cellular Dissociation Grade" showed excellent prognostic demarcation between well (G1), moderately (G2), and poorly differentiated (G3) carcinomas in both scenarios (overall survival: cohort 1: P<0.001; cohort 2: P=0.009) and was predictive for a high pathologic tumor stage and the presence of nodal metastases in primarily resected patients. Multivariate analyses revealed the Cellular Dissociation Grade to be a predictor of poor outcome in the pretherapeutic setting independent of clinical stage (overall survival, disease-free survival, and disease-specific survival: P<0.001). Hazard ratio for disease-free survival was 3.19 for G2 and 5.66 for G3 carcinomas compared with G1 neoplasms. Our data not only prove the transferability of histopathologic grading based on Tumor Budding/Cell Nest Size to biopsy specimens in esophageal squamous cell carcinoma, but also demonstrate that the Cellular Dissociation Grade is a strong outcome predictor in this entity even in the pretreatment scenario. Therefore, we believe that this novel type of grading has the ability to serve as a powerful histology-based pretherapeutic biomarker, that might supplement clinical staging for choosing the most suitable therapy decision.

Identifiants

pubmed: 30807302
doi: 10.1097/PAS.0000000000001230
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

618-627

Auteurs

Moritz Jesinghaus (M)

Institute of Pathology.
German Cancer Consortium (DKTK), Partner Site Munich.
German Cancer Consortium (DKTK), Partner Site Munich, Institute for Translational Cancer Research.

Frido Brühl (F)

Institute of Pathology.

Katja Steiger (K)

Institute of Pathology.
German Cancer Consortium (DKTK), Partner Site Munich.

Peter Klare (P)

II Medizinische Klinik, Klinikum rechts der Isar.

Marianne Reiser (M)

Institute of Pathology.

Alexander Scheiter (A)

Institute of Pathology.

Björn Konukiewitz (B)

Institute of Pathology.

Peer Kuhn (P)

Institute of Pathology.

Stefan Münch (S)

German Cancer Consortium (DKTK), Partner Site Munich.
Department of Radiation Therapy, Klinikum rechts der Isar.

Michael Quante (M)

II Medizinische Klinik, Klinikum rechts der Isar.

Roland M Schmid (RM)

II Medizinische Klinik, Klinikum rechts der Isar.

Dirk Wilhelm (D)

Department of Surgery, Klinikum rechts der Isar, Technical University Munich.

Markus Feith (M)

Department of Surgery, Klinikum rechts der Isar, Technical University Munich.

Helmut Friess (H)

Department of Surgery, Klinikum rechts der Isar, Technical University Munich.

Stephanie E Combs (SE)

German Cancer Consortium (DKTK), Partner Site Munich.
Department of Radiation Therapy, Klinikum rechts der Isar.
Institute of Innovative Radiotherapy (iRT), Helmholtz Center Munich, Munich, Germany.

Dieter Saur (D)

German Cancer Consortium (DKTK), Partner Site Munich.
German Cancer Consortium (DKTK), Partner Site Munich, Institute for Translational Cancer Research.
II Medizinische Klinik, Klinikum rechts der Isar.

Melanie Boxberg (M)

Institute of Pathology.

Wilko Weichert (W)

Institute of Pathology.
German Cancer Consortium (DKTK), Partner Site Munich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH